Paul N. NewtonMichael D. GreenFacundo M. FernándezNicholas PJ DayNicholas J. WhiteMahosot HospitalUniversity of OxfordCenters for Disease Control and PreventionGeorgia Institute of TechnologyMahidol University2018-08-202018-08-202006-09-01Lancet Infectious Diseases. Vol.6, No.9 (2006), 602-613147330992-s2.0-33747341277https://repository.li.mahidol.ac.th/handle/20.500.14594/23638The production of counterfeit or substandard anti-infective drugs is a widespread and under-recognised problem that contributes to morbidity, mortality, and drug resistance, and leads to spurious reporting of resistance and toxicity and loss of confidence in health-care systems. Counterfeit drugs particularly affect the most disadvantaged people in poor countries. Although advances in forensic chemical analysis and simple field tests will enhance drug quality monitoring, improved access to inexpensive genuine medicines, support of drug regulatory authorities, more open reporting, vigorous law enforcement, and more international cooperation with determined political leadership will be essential to counter this threat. © 2006 Elsevier Ltd. All rights reserved.Mahidol UniversityMedicineReviewSCOPUS10.1016/S1473-3099(06)70581-3